The subsidy of pharmaceuticals in Australia: processes and challenges.

39Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

The increasing costs of health care, including new technologies and pharmaceuticals, pose challenges for all countries both in the developed and the developing world. It is essential that the increased expenditure on pharmaceuticals represents value for money and is seen as an investment in health care rather than simply the purchase of the latest released agent. The system in Australia uses a cost-effectiveness approach to guide the decisions as to whether a new drug can be recommended for subsidy. The need for a greater understanding and transparency of the processes is essential in order for a well-informed public debate to occur about the challenges to the system and its sustainability. The relevant issues are discussed in this article to assist that debate.

Cite

CITATION STYLE

APA

Sansom, L. (2004). The subsidy of pharmaceuticals in Australia: processes and challenges. Australian Health Review : A Publication of the Australian Hospital Association, 28(2), 194–205. https://doi.org/10.1071/AH040194

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free